Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-058329
Filing Date
2025-04-25
Accepted
2025-04-25 07:42:43
Documents
28
Period of Report
2025-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A tennx-20250424.htm   iXBRL DEF 14A 1096470
2 GRAPHIC img179895341_0.jpg GRAPHIC 10268
3 GRAPHIC img179895341_1.jpg GRAPHIC 688
4 GRAPHIC img179895341_2.jpg GRAPHIC 702
5 GRAPHIC img179895341_3.jpg GRAPHIC 688
6 GRAPHIC img179895341_4.jpg GRAPHIC 688
7 GRAPHIC img179895341_5.jpg GRAPHIC 688
8 GRAPHIC img179895341_6.jpg GRAPHIC 702
9 GRAPHIC img179895341_7.jpg GRAPHIC 688
10 GRAPHIC img179895341_8.jpg GRAPHIC 702
11 GRAPHIC img179895341_9.jpg GRAPHIC 688
12 GRAPHIC img179895341_10.jpg GRAPHIC 702
13 GRAPHIC img179895341_11.jpg GRAPHIC 688
14 GRAPHIC img179895341_12.jpg GRAPHIC 286840
15 GRAPHIC img179895341_13.jpg GRAPHIC 982757
16 GRAPHIC img179895341_14.jpg GRAPHIC 196673
  Complete submission text file 0000950170-25-058329.txt   5686067

Data Files

Seq Description Document Type Size
17 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tennx-20250424.xsd EX-101.SCH 7796
30 EXTRACTED XBRL INSTANCE DOCUMENT tennx-20250424_htm.xml XML 417896
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-34600 | Film No.: 25870004
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)